New Rules for Antimicrobial Drugs in India: The central government has proposed tighten rules regarding the quality, safety, and efficacy of antimicrobial drugs. The Ministry of Health and Family Welfare has issued a draft of changes in the New Drugs and Clinical Trials Rules 2019. Under this, antimicrobial drugs will be included in the category of new drugs. Due to which direct central supervision over their manufacturing will increase.

What is the new proposal
Through a draft notication (G.S.R. 983(E)) an amendment to Rule 2(1)(w)(v) has been proposed.  If this rule is implemented, pharmaceutical companies will be required to obtain approval from the Central Licensing Authority before securing a manufacturing license from the state authority.

Why is this step being taken
According to the ministry, earlier concerns had come up about many antimicrobial drugs getting manufacturing licenses even without complete testing. To test the right effect and quality of a drug, necessary tests like bioavailability, bioequivalence, and stability should happen. If drugs are weak or less effective, resistance capacity against drugs can increase in bacteria and other

What is antimicrobial resistance
 When the effect of those drugs that the made to kill microorganisms like bacteria, viruses, or fungus starts becoming less or ends on them, then it is called antimicrobial resistance. From this, treatment of even common infections can become difficult. At the global level, it is considered a big health challenge and in the New Delhi Declaration of G20 also, emphasis was given on working together to deal with it.

Suggestions sought within 30 days
This is currently a proposed rule. The Ministry of Health has invited suggestions and objections regarding it from pharmaceutical companies, experts, and the general public. Suggestions may be submitted within 30 days from the date the draft is published in the Gazette.